STVN

Stevanato Group S.p.A.
CAPPED RATING

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. operates as a subsidiary of Stevanato Holding S.R.L.

Stevanato Group S.p.A. (STVN) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Revisions (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B-
Factor Score 2.9 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
B-
Factor Score 3.0 / 5.0
Momentum
C+
Factor Score 2.6 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 26.8
EV / EBITDA 15.1
Rev Growth YoY 7.6%
Gross Margin 29.4%
Price Return 3M -25.7%
Price Return 12M -33.0%
Catalyst Signal 0.00
Market Cap $4.3B
TTM Revenue $1.2B
Price / Sales 3.5
ROE 9.3%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 B- (2.9) C- (2.1) B- (3.0) C+ (2.6) F (0.0) C- (2.1)
2026-11-08 B- (3.0) C- (2.1) B- (3.0) C (2.4) F (0.0) C- (2.1)
2026-11-01 C+ (2.7) C- (2.0) B- (3.0) B- (2.9) C+ (2.7) C+ (2.7)
2026-10-25 C+ (2.8) C- (2.0) B- (3.0) B- (3.0) C+ (2.6) C+ (2.7)
2026-10-18 C+ (2.8) C- (2.0) B- (3.0) B (3.3) C+ (2.6) C+ (2.8)
Page 1 of 3